Towards a pan-European consensus on the treatment of patients with colorectal liver metastases.
about
Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trialHerbal medicines for advanced colorectal cancerHerbal medicines for advanced colorectal cancerCurrent status of transarterial radioembolizationAvoiding hepatic metastasis naturally: Lessons from the cotton top tamarin (Saguinus oedipus)Anti-angiogenic agents in metastatic colorectal cancerLaparoscopic hepatectomy for hepatic colorectal metastases -- a retrospective comparative cohort analysis and literature reviewLaparoscopic-assisted ablation of hepatic tumors: a reviewMultisciplinary management of patients with liver metastasis from colorectal cancerFollow-up strategies for patients treated for non-metastatic colorectal cancer.Yttrium-90 radioembolization for colorectal cancer liver metastases in KRAS wild-type and mutant patients: Clinical and ccfDNA studies.Laparoscopic versus open hepatectomy with or without synchronous colectomy for colorectal liver metastasis: a meta-analysis.Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer.Protocol for Combined Analysis of FOXFIRE, SIRFLOX, and FOXFIRE-Global Randomized Phase III Trials of Chemotherapy +/- Selective Internal Radiation Therapy as First-Line Treatment for Patients With Metastatic Colorectal Cancer.Early prediction of postoperative liver dysfunction and clinical outcome using antithrombin III-activityA randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatmentColorectal cancer: from prevention to personalized medicine.Prognostic Analysis of 102 Patients with Synchronous Colorectal Cancer and Liver Metastases Treated with Simultaneous Resection.Debulking treatment with CT-guided percutaneous radiofrequency ablation and hepatic artery infusion of floxuridine improves survival of patients with unresectable pulmonary and hepatic metastases of colorectal cancermiR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan.Multidisciplinary approach of colorectal cancer liver metastases.Association of primary tumor lymph node ratio with burden of liver metastases and survival in stage IV colorectal cancer.Intraperitoneal ziv-aflibercept effectively manages refractory ascites in colorectal cancer patients.Oncological outcome of unresectable lung metastases without extrapulmonary metastases in colorectal cancer.Cost-effectiveness of first-line treatments for patients with KRAS wild-type metastatic colorectal cancerA systematic review of treatment guidelines for metastatic colorectal cancerPersonalizing medicine for metastatic colorectal cancer: current developments.Neurological Toxicity in Metastatic Colorectal Cancer Patients Treated with Modified FOLFOX6 Plus Bevacizumab.Imaging in resectable colorectal liver metastasis patients with or without preoperative chemotherapy: results of the PROMETEO-01 study.Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality.Metastatic rectal cancer to the breast.Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer.Concomitant Notch activation and p53 deletion trigger epithelial-to-mesenchymal transition and metastasis in mouse gut.Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysisComparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer.HBV infection decreases risk of liver metastasis in patients with colorectal cancer: A cohort study.Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Pattern of distant metastases in colorectal cancer: a SEER based study.FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer.
P2860
Q21260391-578A4B36-5AC2-4598-B546-9FD6E95D6772Q24197971-6AF78511-1B3D-4853-931D-2623F346EC27Q24200914-0A3C4E3C-EE5C-48B0-8F9F-1B35D5F16847Q26744307-A9BE4451-647E-4EA2-BF35-07717B8CA7EEQ26746925-13FA6EE4-E1F3-4271-AC5E-64074B6437DCQ26801911-7CE3EDB5-FD14-4E64-815A-D7E9D0362E22Q26830577-7F1FE283-097D-491F-97DE-DC06AB333401Q27021321-4C61A790-A599-4C8B-918C-3E1D245EF5BDQ28069575-E54BD5E8-9D0B-49B0-B213-2E9EFDC3CC45Q30240736-87E83591-B5F4-4021-8EF9-37DC98980BBAQ30353464-7DBABD10-EB46-4D04-BF23-48A89D04115FQ31149366-72773030-9495-4043-91B5-935BB7EB3A68Q33422070-223445F7-7E42-4D70-82A5-3B2A6CE06C7EQ33555345-B235E02F-5139-47E6-8837-167C687AE9C3Q33562780-C673C4E1-FE69-4E07-A7F8-FE3622C1EAFEQ33715042-CBF30DC8-836C-4A2E-9EDC-E2CBB294946EQ33735234-B7869073-6EB1-4DC8-96DA-1CFDCB2653DFQ33755572-55CF69EA-D665-459B-AC21-A591379D4FD2Q33764110-F700A571-5D23-4B49-BE93-6EC2B0E68E0FQ33773806-F19BE531-ED35-4CD5-A08E-9790C9C82D08Q33779859-25774446-60DF-4E8C-B7D7-128921DEAD19Q33809520-1961E976-8705-4D1B-9B64-14939242E1EDQ33829621-9B27907C-1302-42D1-A6BD-053426CEEEBEQ33978181-5686C309-DB6A-466B-9B48-09ECC18726DEQ33982704-CDDFF372-EC22-47B6-9716-F8FCDB0385CBQ33995028-040AE0AA-DC61-4426-9B7A-F2D0C0886AE0Q34036665-EBAA62BB-3AA2-4C2F-8BF2-200D9355F162Q34049929-2AFEA575-4413-4B83-8663-D6393EA88E48Q34051953-3426C05B-F925-44E6-9F63-D7E8230B148FQ34294365-67E2FBDD-3F80-4D55-B407-59371BD3F5B3Q34362184-4EF50FAE-941A-4350-B002-C5B6834A8CF2Q34364631-A89F7936-71EA-4538-A0D7-5B17D36BEE42Q34372824-078C9167-6CBA-4895-87F0-81174F2B56BFQ34427267-27C979CD-477E-4199-862A-1379FA18D1F1Q34545018-98623EBA-DF96-44C0-BBB9-A710C7A195CCQ34565458-D8B9B955-5FB0-4B5B-829A-276E9A4537D3Q34591251-062AD079-9BDF-40BB-860E-031FDE90EDADQ34664272-4BC0758C-19A0-4033-805E-596479DCB812Q34674089-D7730824-1045-4AFC-B85D-89B7338D1D6FQ34745831-2116C165-1808-422F-9722-5669EDD44176
P2860
Towards a pan-European consensus on the treatment of patients with colorectal liver metastases.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Towards a pan-European consens ...... h colorectal liver metastases.
@ast
Towards a pan-European consens ...... h colorectal liver metastases.
@en
type
label
Towards a pan-European consens ...... h colorectal liver metastases.
@ast
Towards a pan-European consens ...... h colorectal liver metastases.
@en
prefLabel
Towards a pan-European consens ...... h colorectal liver metastases.
@ast
Towards a pan-European consens ...... h colorectal liver metastases.
@en
P2093
P1476
Towards a pan-European consens ...... h colorectal liver metastases.
@en
P2093
Bernard Nordlinger
Carmelo Pozzo
European Colorectal Metastases Treatment Group
Graeme Poston
Marc Ychou
Philippe Rougier
P304
P356
10.1016/J.EJCA.2006.04.012
P577
2006-08-10T00:00:00Z